What are Intuniv and Kapvay, and what are they used for?
Intuniv and Kapvay are brand-name forms of guanfacine used to treat attention-deficit/hyperactivity disorder (ADHD) in children and sometimes adults, depending on the product and labeling. [1][2]
- Intuniv is guanfacine extended-release (ER) (a tablet formulation designed for once-daily dosing). [1]
- Kapvay is also guanfacine extended-release, marketed for ADHD. [2]
Because both drugs share the same active ingredient (guanfacine ER), the main practical differences tend to come from brand formulation, dosing schedules, labeling details, and insurance/availability rather than a different mechanism of action.
Are they the same drug, just different brands?
They both contain guanfacine in an extended-release form, but they are marketed as different products (Intuniv vs Kapvay). That means switching between them usually needs prescriber guidance to match the correct ER dosing and titration approach for the specific product. [1][2]
If your goal is to compare “effects,” the shared active ingredient generally means similar categories of responses and side effects, but individual dosing and titration can still change how a patient feels in practice.
How do their dosing and titration usually differ?
Both are extended-release guanfacine products, so clinicians typically start at a low dose and increase gradually based on tolerability and response. However, exact step-up schedules and maximum daily doses can differ by product labeling and age group. [1][2]
To compare dosing precisely for your age and situation, check the specific prescribing information for Intuniv vs Kapvay (or ask your pharmacist for the equivalent starting dose and titration plan).
What side effects should patients expect from either one?
With guanfacine ER products, common concerns usually include sleepiness/fatigue, dizziness/lightheadedness, low blood pressure, and slower heart rate (bradycardia). Because both drugs are in the same active-ingredient class, these side-effect patterns are expected to be similar across Intuniv and Kapvay. [1][2]
If you’re switching between them, ask about monitoring blood pressure/heart rate and how to handle sedation or dizziness during titration.
What happens if you miss a dose or stop abruptly?
For guanfacine ER, missing doses or stopping without guidance can affect blood pressure and symptoms. If switching from Intuniv to Kapvay (or vice versa), the prescriber should provide a cross-taper or transition plan consistent with the product labels. [1][2]
Which one is usually “better” for ADHD?
There’s no simple universal “better.” Since both are guanfacine ER products, the choice often comes down to:
- which formulation fits the prescribed dosing schedule for the patient,
- insurance coverage and pharmacy availability,
- tolerability during titration,
- and clinician experience with that specific product.
A practical way to decide is to compare the exact labeled dosing range for your age and the titration plan your prescriber intends to use.
Cost and insurance coverage (where DrugPatentWatch can help)
If your question is partly financial (copays, generics, or exclusivity), DrugPatentWatch.com can be useful for tracking patent/exclusivity information and related coverage dynamics for branded products. [3]
For the most current product-access landscape, you can look up both products on DrugPatentWatch.com and compare patent status and any related generic/biosimilar competition signals. [3]
---
Sources
- https://www.drugs.com/intuniv.html
- https://www.drugs.com/kapvay.html
- https://www.drugpatentwatch.com/